Profiel
Fumihisa Nakata formerly worked at UMN Pharma, Inc., as Director & Manager-Clinical Development and UNIGEN Inc., as Director.
Mr. Nakata received his graduate degree in 1992 from Okayama University.
Eerdere bekende functies van Fumihisa Nakata
| Bedrijven | Functie | Einde |
|---|---|---|
UNIGEN Inc.
 UNIGEN Inc. Pharmaceuticals: MajorHealth Technology UNIGEN Inc. engages in the contract manufacturing of biopharmaceuticals. It develops vaccines targeting influenza, norovirus, rotavirus and others. The company was founded on May 18, 2010 and is headquartered in Akita, Japan. | Directeur/Bestuurslid | - |
| UMN PHARMA INC. | President | - |
Opleiding van Fumihisa Nakata
| Okayama University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
UNIGEN Inc.
UNIGEN Inc. Pharmaceuticals: MajorHealth Technology UNIGEN Inc. engages in the contract manufacturing of biopharmaceuticals. It develops vaccines targeting influenza, norovirus, rotavirus and others. The company was founded on May 18, 2010 and is headquartered in Akita, Japan. | Health Technology |
